This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Offer not valid on workshop only or academic/non-profit registrations. Delivered as a Hybrid Event. O’Brien, Pharm.
Informa Connect’s Hub and Specialty Pharmacy Models East. June 28-30, 2022 | Sheraton Parsippany | Parsippany, NJ www.informaconnect.com/hub-specialty-pharmacy. Attorney’s Office, District of New Jersey Lauren Powell, MPA, PhD, Vice President, US Health Equity & Community Wellness, Takeda Pharmaceuticals PLUS! Attorney, U.S.
Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?
A program driven by market dynamics and led by champions of channel strategy, join now to master the complexities of pharmacy and distribution models to accelerate market access –It's all happening December 11-13, 2023. What can you expect?
This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Arquette, R.Ph., REGISTER TODAY.
Dave MacLeod, Head of Patient Services and Specialty Pharmacy Operations , Amylyx Pharmaceuticals Deepti Jaggi, Global Head of Patient Insights and Solutions , Astellas US Marina Allen, Executive Director, Patient Access and Reimbursement , Coherus BioSciences And more! Jourdan Russo, Director, Patient Services , Kyowa Kirin, Inc.
Offer not valid on workshop only or academic/non-profit registrations. Koob, Assistant U.S. Attorney , U.S. Attorney’s Office for the Eastern District of Pennsylvania Jolie Apicella, Assistant U.S. Attorney, Chief, Health Care Fraud , U.S. Register today. Drug Channels, or any of its employees.
Offer not valid on workshop-only or non-profit registrations. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
This alliance with Bristol Myers Squibb is a natural area of collaboration for FAMU, given our College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health,” said Larry Robinson, Ph.D. President of Florida A&M University. “We The 12 doctoral degree programs include 11 doctoral degrees and one Doctor of Public Health.
Based on the results of its evaluation of nominated categories of drug products to date, as well as consultation with the Pharmacy Compounding Advisory Committee (PCAC), FDA is also proposing to include certain categories of drug products on these lists. The rule, will also, if finalized, address communication with State boards of pharmacy.
WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025.
Title Type Date Cleared by OIRA Legal Deadline None Notable FDA Comment Periods Closing in December and January FDA comment periods are typically open for 30-60 days, unless they are extended. ” The report will also cover Federal agency roles in addressing vulnerabilities and statutory limitations.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content